This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
3 of the Best Stocks to Buy for Striking Earnings Growth
by Tirthankar Chakraborty
Crocs (CROX), 1800 FLOWERS.COM (FLWS) and Align Technology (ALGN) are some of the few stocks that have seen superb earnings growth and positive estimate revisions.
Align Technology (ALGN) Beats on Q4 Earnings, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.
Align Technology (ALGN) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 21.96% and 6.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Unit Gets a Boost From New Buyout
by Zacks Equity Research
The Cooper Companies (COO) arm's buyout drives its growing portfolio of medical products, which revolves around clinic and practice-based women's healthcare
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
by Zacks Equity Research
Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.
Abiomed (ABMD) Posts Upbeat Impella SmartAssist Study Results
by Zacks Equity Research
The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.
NextGen Healthcare (NXGN) Loses 8.8% Despite Q3 Earnings Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strong segmental performance.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
ABIOMED's (ABMD) international Impella revenues improve in Q3.
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued recovery in Clear Aligner shipment volumes in Q4.
Align Technology (ALGN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Align Technology (ALGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
Medtronic (MDT) Gets Canada Nod for Micra AV to Treat AV Block
by Zacks Equity Research
With the approval, Medtronic (MDT) aims to strengthen its Cardiac and Vascular Group business globally.
Why You Should Retain Avanos Medical (AVNS) Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.
IDEXX (IDXX) Gains on CAG Sales, Global Growth Remains Robust
by Zacks Equity Research
IDEXX (IDXX) sees sturdy gains in CAG Diagnostics recurring revenues, supported by high organic gains in both U.S. and International markets.
Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base
by Zacks Equity Research
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALGN) Outperforming Other Medical Stocks This Year?
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2021
by Zacks Equity Research
Four large-cap MedTech stocks are currently flourishing on the back of several positive developments
Globus Medical (GMED) Gains From Robot Sales Amid Pandemic Blues
by Zacks Equity Research
Globus Medical (GMED) saw a visible rebound in its revenue trend in the third quarter.
Abbott (ABT) Broadens Pediatric Client Base With New Labeling
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 LVAD or heart pump is an implantable device that pumps blood through the body in people whose hearts are too weak to do so naturally.
Varian (VAR) Inks Deal With Yonsei Cancer Center in Korea
by Zacks Equity Research
Varian (VAR) will be coordinating with Yonsei Cancer Center on formulating AI solutions, which are proven to upgrade early detection of cancer.
Cerner (CERN) to Buy Kantar Health to Enhance Clinical Research
by Zacks Equity Research
Cerner (CERN) agrees to acquire Kantar Health to drive safety and efficiency of clinical research across life sciences, pharmaceuticals and health care.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.